Interference No. 105,188
Short v. Punnonnen
This invention further pertains to expression vectors
containing a nucleic acid encoding at least one peptide
having the activity of a novel B lymphocyte antigen, as
described herein, operably linked to at least one regulatory
5 sequence. . . . .
(Exh. 2040, p. 14, ll. 7-9);
The invention also features methods of producing
10 peptides having an activity of a novel B lymphocyte antigen.
For example, a host cell transfected with a nucleic acid
vector directing expression of a nucleotide sequence
encoding a peptide having activity of the B7-2 protein can
be cultured in a medium under appropriate conditions to
15 allow expression of the peptide to occur. . . . .
(Exh. 2040, p. 14. ll. 29-33);
Transfected cells which express peptides having
20 activity of one or more B lymphocyte antigens (e.g., B7-2,
B7-3) on the surface of the cell are also within the scope
of this invention.
(Exh. 2040, p. 15, ll. 29-31); and
25
[A] peptide having an activity of the B7-2 protein is
defined herein as a peptide having the ability to bind to
the natural ligand(s) of the B7-2 protein on immune cells,
such as CTLA4 and/or CD28 on T cells and either stimulate or
30 inhibit cell costimulation. Thus, a peptide having B7-2
activity binds CTLA4 and/or CD28 and stimulates or inhibits
a T cell mediated immune response (as evidenced by, for
example, cytokine production and/or proliferation by T cells
that have received a primary activation signal). . . .
35 Alternatively, a peptide having both B7-2 binding activity
and the ability to deliver a costimulatory signal to T cells
is used to stimulate or enhance T cell proliferation and/or
cytokine secretion in a subject.
40 (Exh. 2040, p. 16, ll. 22-30; emphasis added).
We find that the Freeman PCT alone describes procedures for
obtaining polynucleotides encoding active B7-2 co-stimulator
-9-
Page: Previous 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next
Last modified: November 3, 2007